Cancer nanomedicines approved so far minimize toxicity, but their efficacy is often limited by
physiological barriers posed by the tumour microenvironment. Here, we discuss how these …

Cancer nanomedicines were initially envisioned as magic bullets, travelling through the
circulation to target tumours while sparing healthy tissues the toxicity of classic …

Nanomedicines are extensively explored for cancer therapy. By delivering drug molecules
more efficiently to pathological sites and by attenuating their accumulation in healthy organs …

The majority of nanomedicines in (pre) clinical trials are based on established drugs, such
as doxorubicin and paclitaxel. Does that make sense? To some extent yes, because a lot of …

The ability to efficiently deliver a drug or gene to a tumor site is dependent on a wide range
of factors including circulation time, interactions with the mononuclear phagocyte system …

The intrinsic limits of conventional cancer therapies prompted the development and
application of various nanotechnologies for more effective and safer cancer treatment …

Malignant tumors remain a major health burden throughout the world and effective
therapeutic strategies are urgently needed. Cancer nanotechnology, as an integrated …

Nanotechnology-based chemotherapeutics and imaging agents represent a new era of
“cancer nanomedicine” working to deliver versatile payloads with favorable …

Anticancer drug resistance almost invariably emerges and poses major obstacles towards
curative therapy of various human malignancies. In the current review we will distinguish …

Cancer continues to be a prevalent and lethal disease, despite advances in tumor biology
research and chemotherapy development. Major obstacles in cancer treatment arise from …